Valérie Calenda
Directeur/Membre du Conseil chez keepMED Ltd.
Profil
Valérie Calenda is currently a Director at keepMED Ltd., Keranova SA, Physio-Assist SAS, Mablink Bioscience SAS, and Amyl Therapeutics SRL.
She is also the Managing Partner at Mérieux Equity Partners SAS since 2010.
Previously, she was a Director at Proclara Biosciences, Inc. and VALKEE Oy.
From 1994 to 2000, she was the Director of Business Development at Transgene, Inc. She was also a Director at ImaginAb, Inc. and a Principal at both the University of California, Davis and the Institut National de la Santé & de la Recherche Médicale.
Dr. Calenda received her undergraduate and doctorate degrees from the University of Marseille.
Postes actifs de Valérie Calenda
| Sociétés | Poste | Début |
|---|---|---|
Mérieux Equity Partners SAS
 Mérieux Equity Partners SAS Investment ManagersFinance Mérieux Equity Partners SAS (Mérieux Equity Partners or MxEP) is a Private Equity and Venture Capital firm, a subsidiary of Mérieux Développement SASU founded in 2009. The firm is headquartered in Lyon, France, with additional offices across the country. | Private Equity Investor | 01/01/2010 |
keepMED Ltd.
 keepMED Ltd. Medical SpecialtiesHealth Technology keepMED Ltd. manufactures innovative devices for treating obstructive sleep apnea. It offers keePAP, a wearable device that comprises of a lightweight unobtrusive nasal interface and a miniature battery-operated control unit that is used for the treatment of obstructive sleep apnea. The company was founded by Rapoport Alex and is headquartered in Rishon Le Zion, Israel. | Directeur/Membre du Conseil | - |
Keranova SA
 Keranova SA Medical SpecialtiesHealth Technology Keranova SA designs and develops surgical equipment for various ophthalmologic indications that involve the anterior segment of the eye. The company was founded by Fabrizio Romano on September 4, 2015 and is headquartered in Saint-Etienne, France. | Directeur/Membre du Conseil | - |
Amyl Therapeutics SRL
 Amyl Therapeutics SRL BiotechnologyHealth Technology Amyl Therapeutics SRL is a Belgian biotech company that uses a novel mechanism to bind to the amyloid fold of toxic protein aggregates of various types, including antibody light chain (AL) or transthyretin (TTR) aggregates, which accumulate in peripheral organs to cause systemic amyloidosis diseases, but also amyloid-? (A?), tau, and ?-synuclein aggregates, which accumulate in the brain to cause Alzheimer's and Parkinson's diseases. Amyl Therapeutics is based in Liege, BE and was founded in November 2020 by Drs. The company's therapies based on the clarity technology platform are designed to prevent the further accumulation of aggregates and clear existing aggregates from the peripheral organs and the brain, while also blocking further cell-to-cell spread of misfolded proteins. Florent Gros and Pierre Vandepapelière. Pierre Vandepapelière has been the CEO since incorporation. | Directeur/Membre du Conseil | - |
Physio-Assist SAS
 Physio-Assist SAS Medical SpecialtiesHealth Technology Physio-Assist SAS develops an expertise in bronchial mucus analysis and clearance. The company was founded by Adrien Mithalal on September 17, 2012 and is headquartered in Aix en Provence, France. | Directeur/Membre du Conseil | - |
Mablink Bioscience
 Mablink Bioscience Pharmaceuticals: MajorHealth Technology Mablink Bioscience is a biotechnology company based in Lyon, France that develops next-generation antibody-drug conjugates for the treatment of solid tumors. Mablink Bioscience's exclusive PSarlink™ platform is a unique stealth technology that "masks" the hydrophobicity of the cytotoxic drugs by adding a polysarcosine chain to the linker. The French company's pipeline is built on the topoisomerase-I inhibitor exatecan as a payload for current developments. Recently, the company announced the publication of a review article titled “Payload Diversification\: A Key Step in the Development of Antibody–Drug Conjugates” which reviews the history of the successes and failures in ADC payloads and takes a look at the new roads currently explored by the industry. The company was founded in 2018 by Warren Viricel and Jean-Guillaume Lafay, with Jean-Guillaume Lafay serving as CEO since then. | Directeur/Membre du Conseil | - |
Anciens postes connus de Valérie Calenda
| Sociétés | Poste | Fin |
|---|---|---|
| Transgene, Inc. | Corporate Officer/Principal | - |
Institut National de la Santé & de la Recherche Médicale
 Institut National de la Santé & de la Recherche Médicale Miscellaneous Commercial ServicesCommercial Services Institut National de la Sant? et de la Recherche M?dicale provides medical services. The firm specializes in biomedical research and public health research. The company is headquartered in Paris, Cedex, France. | Corporate Officer/Principal | - |
VALKEE Oy
 VALKEE Oy Medical SpecialtiesHealth Technology VALKEE Oy develops and manufactures health devices. Its flagship product Valkee is a pocket-sized light therapy device that channels bright light via the ear canals into the brain that has beneficial effects on mood and wellbeing of people. The firm is carrying out additional tests and studies concerning the effects of bright light on cognitive and physical performance and jet lag. The company was founded by Juuso Samuel Nissilä and Antti Aunio in 2007 and is headquartered in Oulu, Finland. | Directeur/Membre du Conseil | - |
| ░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | - |
| ░░░░░░░░░░ ░░ ░░░░░░░░░░░ ░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - |
Formation de Valérie Calenda
| University of Marseille | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 11 |
|---|---|
Proclara Biosciences, Inc.
 Proclara Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Proclara Biosciences, Inc. provides treatment of chronic neurodegenerative diseases. The firm develops therapies for protein misfolding diseases, such as chronic diseases of aging and certain orphan indications by harnessing General Amyloid Interaction Motif (GAIM), which is a multi-target approach that reduces levels of pathological misfolded protein deposits. The company was founded by Hampus Jacob Hillerstrom and Jonathan Eithan Solomon in December 2006 and is headquartered in Cambridge, MA. | Health Technology |
Institut National de la Santé & de la Recherche Médicale
Institut National de la Santé & de la Recherche Médicale Miscellaneous Commercial ServicesCommercial Services Institut National de la Sant? et de la Recherche M?dicale provides medical services. The firm specializes in biomedical research and public health research. The company is headquartered in Paris, Cedex, France. | Commercial Services |
Mérieux Equity Partners SAS
Mérieux Equity Partners SAS Investment ManagersFinance Mérieux Equity Partners SAS (Mérieux Equity Partners or MxEP) is a Private Equity and Venture Capital firm, a subsidiary of Mérieux Développement SASU founded in 2009. The firm is headquartered in Lyon, France, with additional offices across the country. | Finance |
VALKEE Oy
VALKEE Oy Medical SpecialtiesHealth Technology VALKEE Oy develops and manufactures health devices. Its flagship product Valkee is a pocket-sized light therapy device that channels bright light via the ear canals into the brain that has beneficial effects on mood and wellbeing of people. The firm is carrying out additional tests and studies concerning the effects of bright light on cognitive and physical performance and jet lag. The company was founded by Juuso Samuel Nissilä and Antti Aunio in 2007 and is headquartered in Oulu, Finland. | Health Technology |
| Transgene, Inc. | |
ImaginAb, Inc.
 ImaginAb, Inc. Medical SpecialtiesHealth Technology ImaginAb, Inc. develops engineered antibody fragments for diagnostic imaging and novel therapeutic applications. It products offer actionable data to facilitate diagnosis of disease, inform better treatment decisions, and monitor response to therapy. The firm also offers a range of pre-clinical (animal imaging) reagents for use with microPET, microSPECT, and optical imaging systems. The company was founded by Christian P. Behrenbruch, Tove Olafsen, Anna M. Wu, and Robert E. Reiter in 2007 and is headquartered in Inglewood, CA. | Health Technology |
keepMED Ltd.
keepMED Ltd. Medical SpecialtiesHealth Technology keepMED Ltd. manufactures innovative devices for treating obstructive sleep apnea. It offers keePAP, a wearable device that comprises of a lightweight unobtrusive nasal interface and a miniature battery-operated control unit that is used for the treatment of obstructive sleep apnea. The company was founded by Rapoport Alex and is headquartered in Rishon Le Zion, Israel. | Health Technology |
Keranova SA
Keranova SA Medical SpecialtiesHealth Technology Keranova SA designs and develops surgical equipment for various ophthalmologic indications that involve the anterior segment of the eye. The company was founded by Fabrizio Romano on September 4, 2015 and is headquartered in Saint-Etienne, France. | Health Technology |
Physio-Assist SAS
Physio-Assist SAS Medical SpecialtiesHealth Technology Physio-Assist SAS develops an expertise in bronchial mucus analysis and clearance. The company was founded by Adrien Mithalal on September 17, 2012 and is headquartered in Aix en Provence, France. | Health Technology |
Mablink Bioscience
Mablink Bioscience Pharmaceuticals: MajorHealth Technology Mablink Bioscience is a biotechnology company based in Lyon, France that develops next-generation antibody-drug conjugates for the treatment of solid tumors. Mablink Bioscience's exclusive PSarlink™ platform is a unique stealth technology that "masks" the hydrophobicity of the cytotoxic drugs by adding a polysarcosine chain to the linker. The French company's pipeline is built on the topoisomerase-I inhibitor exatecan as a payload for current developments. Recently, the company announced the publication of a review article titled “Payload Diversification\: A Key Step in the Development of Antibody–Drug Conjugates” which reviews the history of the successes and failures in ADC payloads and takes a look at the new roads currently explored by the industry. The company was founded in 2018 by Warren Viricel and Jean-Guillaume Lafay, with Jean-Guillaume Lafay serving as CEO since then. | Health Technology |
Amyl Therapeutics SRL
Amyl Therapeutics SRL BiotechnologyHealth Technology Amyl Therapeutics SRL is a Belgian biotech company that uses a novel mechanism to bind to the amyloid fold of toxic protein aggregates of various types, including antibody light chain (AL) or transthyretin (TTR) aggregates, which accumulate in peripheral organs to cause systemic amyloidosis diseases, but also amyloid-? (A?), tau, and ?-synuclein aggregates, which accumulate in the brain to cause Alzheimer's and Parkinson's diseases. Amyl Therapeutics is based in Liege, BE and was founded in November 2020 by Drs. The company's therapies based on the clarity technology platform are designed to prevent the further accumulation of aggregates and clear existing aggregates from the peripheral organs and the brain, while also blocking further cell-to-cell spread of misfolded proteins. Florent Gros and Pierre Vandepapelière. Pierre Vandepapelière has been the CEO since incorporation. | Health Technology |
